Pharmaceutical application of rapamycin to refractory GD (Graves diseases)

A rapamycin, refractory technology, applied in the field of pharmaceutical application of rapamycin in refractory Graves' disease, can solve the problems that rapamycin has not been reported in the treatment, and achieve the goal of improving plasma levels Effect

Active Publication Date: 2020-09-15
THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the application of rapamycin in the treatment of refractory Graves disease has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of rapamycin to refractory GD (Graves diseases)
  • Pharmaceutical application of rapamycin to refractory GD (Graves diseases)
  • Pharmaceutical application of rapamycin to refractory GD (Graves diseases)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0028] In order to enable those skilled in the art to better understand the solutions of the present invention, the following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only It is an embodiment of a part of the present invention, but not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts shall fall within the protection scope of the present invention.

[0029] It should be noted that the terms "first" and "second" in the description and claims of the present invention and the above drawings are used to distinguish similar objects, but not necessarily used to describe a specific sequence or sequence. It is to be understood that the data so used are interchangeable under appropriate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses pharmaceutical application of rapamycin to refractory GD (Graves diseases) for the first time. Through combined treatment by the rapamycin and methimazole, the TSH and TRAb levels of a patient with the refractory GD can be improved; in addition, the Treg / CD4+T proportion in the body of the patient is raised; the Th17 / CD4+T proportion and the Th17 / Treg ratio are reduced; andmeanwhile, the plasma levels of Th17 and Treg cell related cell factors including IL-17A, IL-6 and TGF-beta 1 are obviously improved. The refractory GD dosage of the rapamycin is 0.5 mg / d, and the drug minimal concentration is 2 to 4 ng / mL. A rapamycin and methimazole combined treatment group does not have obvious untoward effects. Therefore, experiment results of the invention sufficiently support novel application of the rapamycin to the treatment of the refractory GD; and the combined treatment by the rapamycin and the methimazole is a worth exploring novel direction for the refractory GD.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to the pharmaceutical application of rapamycin in refractory Graves' disease. Background technique [0002] Graves' disease (GD) is a common organ-specific autoimmune disease and the most common cause of hyperthyroidism. The annual incidence of GD is (20-50) / 100,000, and about 3% of women and 0.5% of men suffer from GD for life. Among them, GD patients who received antithyroid drug therapy for more than 5 years, and those with normal or mild hyperthyroidism were defined as refractory GD. Based on our previous studies, refractory and regulatory T cells (Treg) / CD4+T, Th17 / CD4+T ratio, and Th17 / Treg ratio in GD compared with GD group in remission and healthy control group Moreover, the expression levels of Th17 and Treg cell-related cytokines IL-17A, IL-6, TGF-β1, IL-1β and IL-10 in plasma of refractory GD patients were significantly higher than those of healthy controls. At presen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/436A61K31/4164A61P37/02A61P5/14
CPCA61K31/4164A61K31/436A61P5/14A61P37/02A61K2300/00
Inventor 施秉银王悦陈子怡胡诗倩
Owner THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap